Postinfarction ventricular septal rupture (PIVSR) is a rare but serious complication of acute myocardial infarction. Determining how to conduct surgical repair safely is critical. We compared the outcomes of Impella and intra-aortic balloon pump (IABP) implantation during perioperative mechanical circulatory support management in patients with PIVSR (n = 22). The primary endpoint was the 12-month survival rate. Secondary endpoints included major adverse cardiovascular events (MACEs) and the number of waiting days for surgery. Using the log-rank test, we compared Kaplan-Meier curves between the groups. The 12-month survival rate was 87.5% and 53.6% in the Impella and IABP groups, respectively, with no significant difference (p = 0.17). The median number of days from circulatory support implantation to surgery was longer in the Impella group than in the IABP group (2.5 days vs. 1.0 days, interquartile range: 1.8-5.2 vs. 0-1.0; p = 0.003). In the subgroup analysis considering only the Society for Cardiovascular Angiography and Interventions (SCAI) shock stages B-D, the 12-month survival rate was higher (85.7% vs. 18.8%; p = 0.03) and the MACE rate was lower (14.3% vs. 53.3%; p = 0.010) in the Impella group than in the IABP group. In summary, when focusing on the SCAI shock stages B-D, the Impella group had significantly better outcomes than did the IABP group. In the perioperative management of PIVSR, the use of Impella may be more beneficial than the use of IABPs, particularly in patients with SCAI shock stages B-D.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00380-025-02513-x | DOI Listing |
Ann Vasc Surg
January 2025
The Leeds Vascular Institute, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK. Electronic address:
Objective: The Achilles' heel of infrainguinal bypass grafts (IIBG) is restenosis. Duplex ultrasound (DUS) surveillance is commonly undertaken to identify restenosis allowing intervention for graft salvage. We report the impact of DUS surveillance on patient outcomes alongside healthcare-associated costs.
View Article and Find Full Text PDFHeart Vessels
January 2025
Saitama Sekishinkai Hospital, 2-37-20 Irumagawa, Sayama, Saitama, Japan.
Postinfarction ventricular septal rupture (PIVSR) is a rare but serious complication of acute myocardial infarction. Determining how to conduct surgical repair safely is critical. We compared the outcomes of Impella and intra-aortic balloon pump (IABP) implantation during perioperative mechanical circulatory support management in patients with PIVSR (n = 22).
View Article and Find Full Text PDFLife (Basel)
December 2024
Interventional Endoscopy Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Background And Aims: Despite technical advances, endoscopic retrograde cholangiopancreatography (ERCP) is associated with complications and potentially lethal outcomes. Sarcopenia, a complex syndrome mainly associated with aging, has been recognized as a predictor of poor surgical outcomes. Thus far, the impact of sarcopenia on ERCP remains unknown.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Department of Oncology, The Royal Surrey Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.
Melanoma poses significant challenges due to its resistance to conventional therapies and increasing incidence rates. Stage III melanoma, characterised by regional lymph node involvement, has a high risk of recurrence despite surgical resection. Adjuvant immunotherapy, particularly using the PD-1 inhibitors pembrolizumab and nivolumab, has shown promising results in improving recurrence-free survival (RFS) and overall survival (OS) in Stage III melanoma patients.
View Article and Find Full Text PDFNPJ Precis Oncol
January 2025
University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.
We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!